**HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE – June 2011**

CILOSTAZOL, NAFTIDROFURYL OXALATE, PENTOXIFYLLINE AND INOSITOL NICOTINATE FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN PEOPLE WITH PERIPHERAL ARTERIAL DISEASE, NICE TA223, MAY 2011

**NAFTIDROFURYL OXALATE – RECOMMENDED**

**CILOSTAZOL, PENTOXIFYLLINE AND INOSITOL NICOTINATE – NOT RECOMMENDED**

<table>
<thead>
<tr>
<th>Names: generic (trade)</th>
<th>What they are</th>
<th>Indication</th>
<th>Date decision last revised</th>
<th>Decision Status</th>
<th>NICE / SMC Guidance</th>
</tr>
</thead>
</table>

**HMMC Recommendation:**

**NAFTIDROFURYL OXALATE - RECOMMENDED FOR RESTRICTED USE** as an **OPTION** only if the following criteria **ALL** apply:

- Patient is an adult.
- Smoking cessation has not relieved symptoms.
- Increasing exercise has not relieved symptoms.
- Naftidrofuryl oxalate must be prescribed generically, not by brand name.

**CILOSTAZOL, PENTOXIFYLLINE AND INOSITOL NICOTINATE – NOT RECOMMENDED**

Patients receiving these treatments should be reviewed and if treatment is required and there are no contra-indications, naftidrofuryl oxalate should be prescribed.

Cilostazol was the subject of an MHRA drug safety update in April 2013 with further contraindications and restrictions on use. The details of this alert are available at: [http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con267913.pdf](http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con267913.pdf)

This decision is to be incorporated into any locally agreed treatment protocols and algorithms.


Produced by Hertfordshire Pharmacy and Medicines Optimisation Team
Hertfordshire, Bedfordshire and Luton Commissioning Support
NHS Central Eastern Commissioning Support Unit

This HMMC recommendation is based upon the evidence available at the time of publication. The recommendation will be reviewed upon request in the light of new evidence becoming available.